OUR COVID-19 LESSONS.

I was a senior researcher at the National Institutes of Health, leading a team that developed a COVID-19 vaccine. It is often deemed "miraculous" that our COVID-19 vaccine progressed to a Phase 1 clinical trial in merely 66 days, but the process could have been even more efficient had our technology gone into Phase 1 clinical trial before the pandemic. The strides we made were not because of any extraordinary funding streams, but merely because we were interested in closing gaps in scientific understanding - particularly in light of the recent threats posed by SARS-1 and MERS, which showed the pandemic potential of coronaviruses. [Extracted from the article]

Copyright of TIME Magazine is the property of TIME USA, LLC and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)